ncRNAs编排化学敏感性诱导通过缩阻塞
Andrea Pérez-González1, Ivonne Ramírez-Díaz1,2, Josué Guzmán-Linares1
1International Laboratory EPIGEN, Consejo de Ciencia y Tecnología del Estado de Puebla (CONCYTEP), Instituto de Ciencias, Ecocampus, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla 72570, Mexico.
Cancers
|February 24, 2024
概括
化抑制剂MLN4924可以逆转肺癌细胞的干性和上皮-介质细胞过渡. 这一发现为新的肺癌疗法提供了潜力,通过恢复化学敏感性和促进分化.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 肺腺癌 (LUAD) 对像gefitinib这样的向疗法具有抗性.
- 癌症干和上皮-介质细胞过渡 (EMT) 是药物耐药性和瘤进展的关键驱动因素.
- 缩是一种翻译后的修改,涉及到调节癌症中的蛋白质稳定性和功能.
研究的目的:
- 为了研究缩抑制剂MLN4924对肺腺癌细胞的转录效应.
- 探索ncRNA表达,干性因子和LUAD中药物耐药性之间的关系.
- 为了确定MLN4924是否可以逆转gefitinib抗性LUAD细胞中的干细胞和EMT表型.
主要方法:
- 在A549和PC9GR细胞系的整合性转录基因 in silico分析.
- 用缩抑制剂MLN4924进行治疗.
- 差异基因表达分析专注于ncRNAs和干性因子.
- 对差异表达基因的途径丰富分析.
主要成果:
- 在A549细胞中,MLN4924治疗调高了亲致癌和分化途径,同时降低了A549细胞的干性和生存途径;PC9GR细胞显示了相反的效果.
- 在MLN4924治疗后升级的ncRNA与干性因子表达相反相关.
- 在PC9GR细胞中的MLN4924废除的干度 (KLF4,FGFR2) 和EMT (ZEB2,TWIST2,SNAI2,CDH2,VIM) 因素.
- 调节后的ncRNAs针对在增殖,分化和亡途径中丰富的mRNAs.
- 下调的ncRNA针对干细胞维护中的mRNA.
结论:
- 通过MLN4924的缩抑制可以逆转肺癌细胞中的干性和EMT表型.
- MLN4924促进表皮分化通路,可能在肺癌中起到保护作用.
- 向缩是一种有希望的策略,可以增强化学敏感性,并对抗肺部瘤发生.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
202
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
202
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
278
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
278
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


